MedImmune Receives FDA Notice For Motavizumab
Motavizumab is an investigational humanized monoclonal antibody (MAb) being evaluated for its potential to prevent serious lower respiratory tract disease caused by espiratory syncytial virus (RSV) in pediatric
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.